Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1978 Sep 2;2(6138):655–657. doi: 10.1136/bmj.2.6138.655

Polymorphism of carbon oxidation of drugs and clinical implications.

T P Sloan, A Mahgoub, R Lancaster, J R Idle, R L Smith
PMCID: PMC1607381  PMID: 151576

Abstract

Eight volunteers previously phenotyped for their ability to hydroxylate debrisoquine (four extensive metabolisers (EM), four poor metabolisers (PM) were investigated for their metabolic handling of guanoxan and phenacetin. All three drugs are oxidised at carbon centres. Oxidative dealkylation of phenacetin was determined by measuring the rate of formation of paracetamol. The EM subjects excreted mostly metabolites of guanoxan (mean 29% of dose), whereas the PM group excreted large amounts of unchanged drug (48% of dose). The rate of formation of paracetamol was noticeably slower in the PM group, and, when analysed by minimum estimates of apparent first-order rate constants, the difference between the two phenotypes was significant. Thus the hydroxylation defect shown for debrisoquine metabolism carries over to the oxidative metabolism of phenacetin and guanoxan. Some 5% of the population are genetically defective hydroxylators of drugs. Thus methods for evaluating the metabolism of new drugs in respect of usage and side effects need to be revised.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chafetz L., Daly R. E., Schriftman H., Lomner J. J. Selective colorimetric determination of acetaminophen. J Pharm Sci. 1971 Mar;60(3):463–466. doi: 10.1002/jps.2600600328. [DOI] [PubMed] [Google Scholar]
  2. Cummings A. J., King M. L., Martin B. K. A kinetic study of drug elimination: the excretion of paracetamol and its metabolites in man. Br J Pharmacol Chemother. 1967 Feb;29(2):150–157. doi: 10.1111/j.1476-5381.1967.tb01948.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Drayer D. E., Reidenberg M. M. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther. 1977 Sep;22(3):251–258. doi: 10.1002/cpt1977223251. [DOI] [PubMed] [Google Scholar]
  4. Erdtmansky P., Goehl T. J. Gas-liquid chromatographic electron capture determination of some monosubstituted guanido-containing drugs. Anal Chem. 1975 Apr;47(4):750–752. doi: 10.1021/ac60354a049. [DOI] [PubMed] [Google Scholar]
  5. Idle J. R., Mahgoub A., Lancaster R., Smith R. L. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci. 1978 Mar;22(11):979–983. doi: 10.1016/0024-3205(78)90363-6. [DOI] [PubMed] [Google Scholar]
  6. Jack D. B., Stenlake J. B., Templeton R. The metabolism and excretion of guanoxan in man. Xenobiotica. 1972 Jan;2(1):35–43. doi: 10.3109/00498257209036232. [DOI] [PubMed] [Google Scholar]
  7. Lunde P. K., Frislid K., Hansteen V. Disease and acetylation polymorphism. Clin Pharmacokinet. 1977 May-Jun;2(3):182–197. doi: 10.2165/00003088-197702030-00003. [DOI] [PubMed] [Google Scholar]
  8. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  9. Martin B. K. Treatment of data from drug urinary excretion. Nature. 1967 Apr 15;214(5085):247–249. doi: 10.1038/214247a0. [DOI] [PubMed] [Google Scholar]
  10. Shahidi N. T. Acetophenetidin-induced methemoglobinemia. Ann N Y Acad Sci. 1968 Jul 31;151(2):822–832. doi: 10.1111/j.1749-6632.1968.tb48266.x. [DOI] [PubMed] [Google Scholar]
  11. Vesell E. S. Genetic and environmental factors affecting drug response in man. Fed Proc. 1972 Jul-Aug;31(4):1253–1269. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES